Stage 1非セミノーマ睾丸腫瘍に対するbleomycin, vincristine, methotrexate併用化学療法

Abstract

stage 1非セミノーマ睾丸腫瘍10例に除睾術後BLM, VCR, MTXの3剤による併用化学療法をおこなった.1) BOM療法は除睾術後の後療法とし有効で, 10例全例が1年6ヵ月～5年3ヵ月(平均3年9ヵ月)生存している.2)中途半端な治療では再発するので, 最低1年間は維持療法を続ける必要がある.3) BOM療法は毒性が低く, 早期副作用には重篤なものはなかった.4)以上よりBOM療法はstage 1非セミノーマに対する後療法とし, 後腹膜リンパ節廓清術や放射線治療と同様に有効と考えた

Ten patients with Stage I non-seminomatous germ cell testicular tumors underwent orchiectomy and combination chemotherapy with bleomycin, vincristine and methotrexate with CF rescue (BOM) as an induction therapy followed by cyclophosphamide, vincristine and methotrexate as a maintenance therapy (COM). The results were as follows: BOM seemed to be effective as a further treatment for Stage I non-seminomatous germ cell testicular tumor patients. All 10 patients are alive and disease-free for a period from 1 year and 6 months to 5 years and 3 months (mean: 3 years and 9 months). The chemotherapy should be continued at least for a year, since relapse occurred in 2 of 4 patients who received only induction therapy. However, they completely responded to other chemotherapy regimens (BVP and BOAM ). BOM and COM therapy were scarcely toxic and no serious side effects were recognized. From the above results, it was considered that combination chemotherapy (BOM and COM) can be an alternative treatment to the conventional retroperitoneal node dissection and radiation therapy for Stage I non-seminomatous germ cell tumors.